Research news
Researchers have found that graphene quantum dots (GQDs) could provide a new approach for studying and potentially disrupting the protein aggregation processes associated with neurodegenerative diseases such as Parkinson’s disease.
A multinational research team led by scientists at Poznań University of Medical Sciences investigated how these nanoscale carbon-based materials interact with α-synuclein, a protein that forms toxic aggregates linked to Parkinson’s disease and multiple system atrophy.
Published in Science and Technology of Advanced Materials, the study [1] found that GQDs could interfere with the formation of α-synuclein fibres, reducing the development of structures associated with neuronal damage.
The researchers tested the materials across several models, including laboratory assays, neuronal cell cultures and animal studies. In mice, intranasal administration of GQDs reduced toxic protein aggregates and appeared to stimulate autophagy - a natural cellular process involved in removing damaged proteins.
While the findings highlight the potential of nanomaterials as tools for investigating protein misfolding disorders, the researchers emphasise that further work is needed to understand safety, biological interactions and long-term effects before clinical applications can be considered.
Professor Małgorzata Kujawska, who led the study, said: “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research into nanomaterial-based strategies for neurodegenerative diseases.”
The team suggests that optimising graphene quantum dots could help advance future approaches not only for Parkinson’s-related conditions but also for other diseases involving toxic protein accumulation.
More information online
ILM 51.5 July 2026